Galapagos NV : Galapagos increases share capital through warrant exercises

  Galapagos NV : Galapagos increases share capital through warrant exercises

Mechelen, Belgium;  8April2013 -  Galapagos  NV (Euronext:  GLPG)  announced 
today a capital increase arising from employee warrant exercises.

Since its inception in 1999, Galapagos  has used warrant plans to  incentivize 
personnel and management and have them  share in the success of the  company. 
Following warrant  exercises  during  the exercise  period  from  9March2013 
through  29March2013,  Galapagos  issued  197,581  new  ordinary  shares  on 
5April2013 for  a total  capital increase  (including issuance  premium)  of 

CEO Onno van de  Stolpe exercised 50,000 warrants,  granted in 2008 and  which 
were due to expire on 25 June 2013. Of these, 20,000 were exercised through a
cashless exercise facility to  finance the cash  exercise of 30,000  warrants. 
Onno van de Stolpe's  shareholding in Galapagos  thereby increased by  30,000 
shares to a  total of 355,448  shares, or 1.32%  of the outstanding  Galapagos 

To date, Galapagos' total share capital amounts to €145,884,501.48; the  total 
number of securities conferring voting rights is 26,968,328, which is also the
total  number  of  voting  rights  (the  "denominator"),  and  all  securities 
conferring voting rights and all voting rights are of the same category.  The 
total number of rights  (warrants) to subscribe to  not yet issued  securities 
conferring voting rights is 3,123,368, which equals the total number of voting
rights that may result  from the exercise of  these warrants. Galapagos  does 
not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos   (Euronext:   GLPG;   OTC:   GLPYY)   is   specialized   in   novel 
modes-of-action, with a large pipeline of four clinical, six pre-clinical, and
30  discovery  small-molecule  and  antibody  programs  in  cystic   fibrosis, 
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about  to 
enter Phase  2b studies.  AbbVie  and Galapagos  signed a  worldwide  license 
agreement whereby  AbbVie  will be  responsible  for further  development  and 
commercialization after  Phase  2b.  Galapagos  has  another  selective  JAK1 
inhibitor in Phase 2  in lupus and  psoriasis, GSK2586184 (formerly  GLPG0778, 
in-licensed by  GlaxoSmithKline  in  2012).  GLPG0187  is  a  novel  integrin 
receptor antagonist  currently in  a Phase  1b patient  study in  metastasis. 
GLPG0974 is the  first inhibitor of  FFA2 to be  evaluated clinically for  the 
treatment of IBD; this program will start a Proof of Concept Phase 2 study  in 
Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees  and operates facilities in five  countries, 
with global  headquarters  in  Mechelen,  Belgium.  Further  information  at:


Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

This  release  may  contain  forward-looking  statements,  including,  without 
limitation,  statements  containing   the  words  "believes,"   "anticipates," 
"expects," "intends," "plans," "seeks,"  "estimates," "may," "will,"  "could," 
"stands  to,"  and   "continues,"  as  well   as  similar  expressions.   Such 
forward-looking statements may involve known and unknown risks,  uncertainties 
and other factors which might  cause the actual results, financial  condition, 
performance  or  achievements  of  Galapagos,  or  industry  results,  to   be 
materially  different  from   any  historic  or   future  results,   financial 
conditions,  performance  or  achievements   expressed  or  implied  by   such 
forward-looking statements. Given these uncertainties, the reader is  advised 
not to place  any undue  reliance on such  forward-looking statements.  These 
forward-looking statements speak only  as of the date  of publication of  this 
document. Galapagos expressly  disclaims any  obligation to  update any  such 
forward-looking statements  in this  document  to reflect  any change  in  its 
expectations with  regard  thereto or  any  change in  events,  conditions  or 
circumstances on which any such statement is based, unless required by law  or 

Galapagos increases share capital through warrant exercises


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.